首页> Journal of neuroimmunology> Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation.

Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Allison,Kraus

第一单位： Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. Electronic address: allison.kraus@nih.gov.

作者： Allison,Kraus ^[1] ; Brent,Race ^[2] ; Katie,Phillips ^[2] ; Clayton,Winkler ^[2] ; Greg,Saturday ^[3] ; Michael,Kurnellas ^[4] ; Jonathan B,Rothbard ^[5] ; Bradley R,Groveman ^[2] ; Lawrence,Steinman ^[5] ; Byron,Caughey ^[2]

作者单位： Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. Electronic address: allison.kraus@nih.gov. ^[1] Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. ^[2] Rocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. ^[3] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA. ^[4] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA. ^[5]

关键词 Amyloid Experimental autoimmune encephalomyelitis Prion protein